摘要
重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)能够有效防治化疗引起的中性粒细胞减少症,其主要通过肾脏代谢,药物半衰期短,需重复注射以维持药效。聚乙二醇(polyethylene glycol,PEG)与rhG-CSF经共价结合制备为PEG-rhG-CSF,可延长药物半衰期,但其在临床应用中可出现由免疫原性介导的不良反应,是需要关注的安全性问题。本文就PEG-rhG-CSF免疫原性引发的不良反应及免疫原性的影响因素、检测方法、产生机制等作一综述,以期为PEG-rhG-CSF的临床安全应用提供参考。
Recombinant human granulocyte-colony stimulating factor(rhG-CSF)can effectively prevent and treat febrile neutropenia caused by chemotherapy,which mainly metabolizes through the kidneys and has a short half-life,requiring repeated injections to maintain its effect.PEG-rhG-CSF formed by combining polyethylene glycol(PEG)with rhG-CSF can prolong the half-life of drugs.However,there have been immunogenicity mediated adverse reactions in clinical use of PEG-rhG-CSF,and the safety is still the focus of attention.This paper discusses the adverse reactions induced by PEG-rhG-CSF immunogenicity,as well as the influencing factors,detection methods and production mechanism of immunogenicity with the aim of providing reference for the safe clinical application of PEG-rhG-CSF.
作者
王丹阳
徐婷婷(综述)
邱云良(审校)
WANG Danyang;XU Tingting;QIU Yunliang(School of Chemistry and Chemical Engineering,Shanghai University of Engineering Science,Shanghai 201620,China)
出处
《中国生物制品学杂志》
CAS
CSCD
2024年第8期1002-1007,共6页
Chinese Journal of Biologicals
基金
上海市科委工程技术研究中心专项(17DZ2252900)。
关键词
重组人粒细胞集落刺激因子
聚乙二醇
免疫原性
抗药抗体
不良反应
Recombinant human granulocyte-colony stimulating factor(rhG-CSF)
Polyethylene glycol(PEG)
Immunoge-nicity
Antidrug antibody(ADA)
Adverse reactions
